Standard BioTools Completes Sale of SomaLogic to Illumina for $350M
ByAinvest
Friday, Jan 30, 2026 9:21 am ET1min read
ILMN--
LAB--
Standard BioTools has completed the sale of SomaLogic to Illumina for $350 million in upfront cash and up to $75 million in near-term earnout payments, totaling $425 million. The deal leaves Standard BioTools with approximately $550 million in cash and cash equivalents on its balance sheet, excluding potential future earnouts. The company is on track to achieve positive adjusted EBITDA in 2026 and plans to use the funds to fuel its inorganic growth strategy.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet